Bausch Health Companies has announced the acquisition of DURECT Corporation. According to the company announcement Bausch Health Companies Inc. is a global, diversified pharmaceutical company dedicated to improving healthcare outcomes. The company develops, manufactures, and markets a variety of products, primarily focusing on gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health through its controlling interest in Bausch + Lomb Corporation. Bausch Health is set to acquire DURECT Corporation, a move that will strengthen its commitment to developing innovative solutions for patients with liver disease. This acquisition includes larsucosterol, a novel therapeutic molecule that has shown promising results in Phase 2 trials for the treatment of alcoholic hepatitis (AH), a life-threatening form of alcohol-associated liver disease with no currently approved treatments.

To learn more about Bausch Health Companies, visit http://www.bauschhealth.com/
Company LinkedIn Page: https://www.linkedin.com/company/bausch-health-companies/

Company Contact:

Thomas Appio, Chief Executive Officer
866-246-8245

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.